No Data
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Devonian Reports Positive Results in MASH Liver Study
Devonian Health Brief: Revenue for Dexlansoprazole Represented 86% and 92% of Total Reported Revs for Fiscal Year Ended July 31, 2024, and Quarter Ended October 31,2024, Respectively
Devonian Health Brief: Relates to the Distribution of Dexlansoprazole for an Additional Term
Devonian Health Brief: Announcing a Pharmaceutical Distribution Division Has Been Informed That One of Its Licensor Does Not Intend to Exercise Its Contractual License Renewal Option
Devonian Reports Distribution Agreement Termination
